ILMN Illumina Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
15:34
Oct 10
Oct 10
r/stocks
Long ILMN as indirect GRAIL play via 7% stake
The author suggests that more skeptical investors can invest in ILMN as an alternative play on GRAL because Illumina owns just over 7% of GRAIL, providing indirect exposure to the same MCED opportunity. The thesis is a buy recommendation on ILMN as a way to participate in GRAIL's long-term potential while mitigating direct single-stock risk.
11:50
Oct 03
Oct 03
Chesley Investment Advisory
NGS demand rising; buy sequencing equipment.
NGS (next-generation sequencing) demand is rising strongly, led by Illumina, Natera, and Tempus. ASPs are increasing, penetration is still low, and fundamentals are good, making it a strong biotech equipment area.
16:16
Sep 30
Sep 30
Monetary Matters
AI drug discovery tools beat picking winners
AI can now model cells, organs, tissue, and disease biology at scale and screen molecules computationally, shifting drug discovery from expensive trial-and-error toward data-driven target selection. Rather than picking which drug company wins, Ben prefers the tools that measure, test, collect, create, and sequence biological data, citing a basket including Danaher, Thermo Fisher, Schrödinger, Illumina, Guardant Health, and Twist Bioscience.
About ILMN Investor Commentary
Across the available history and selected sources, Buzzberg tracks ILMN (Illumina Inc.) across 20 sources: 12 bullish vs 0 bearish calls from 24 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 36 total trade ideas tracked. Latest voices: u/Odd-Web4113, Shin Woo-young, Ben Pouladian.